CompletedNCT00644969
Varenicline or placebo with counseling to stop smoking in schizophrenia
About this title
Read the official source — NCT00644969Medication studyAges 18–75United States + Canada
Understand this study
Who was this study for?
Listed age limits: 18 years to 75 years.
- Listed locations
- Aurora and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 128
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00644969
- Official title
Show the full official title
A Phase 3B 12-Week, Double -Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Varenicline Tartrate (CP-526,555) 1 mg BID for Smoking Cessation in Subjects With Schizophrenia and Schizoaffective Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Aurora, United States · Farmington, United States · New Haven, United States
9 more locations
- Worcester, United States
- New Brunswick, United States
- Durham, United States
- Cincinnati, United States
- Pittsburgh, United States
- Houston, United States
- Edmonton, Canada
- Mississauga, Canada
- Toronto, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Pfizer.
Did this study involve medication?
Yes. The study involved medication, including placebo and varenicline (CP-526,555).
Who was this study for?
Listed age limits: 18 years to 75 years.
